Therapeuticsmd, Inc. insider trading
Every open-market purchase and sale by Therapeuticsmd, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Therapeuticsmd, Inc.’s insiders pay?
From December 22, 2010 to December 29, 2025, 21 insiders reported 43 open-market purchases and 18 sales not made under a pre-set plan in Therapeuticsmd, Inc. Twelve months after each purchase was reported, the shares were −34.2% against the S&P 500 on average (median −41.6%), over 15 purchases with a full year of prices; 27% beat the index. After sales, the shares moved −34.9% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 13, 2015 into $1,844 by November 2, 2026, −13.7% a year. It held shares 45% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $19,946 (+6.2% a year), and held throughout $43,521 (+13.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Thompson Tommy G | Director | 9 | −19.6% (5) | 40% | 0 | — | December 29, 2025 |
| Collins Cooper C. | Director | 6 | −8.0% (1) | 0% | 1 | — | November 22, 2021 |
| Finizio Robert G | CEO | 5 | — | — | 2 | −16.7% (1) | May 12, 2021 |
| Milligan John C.K. IV | Secretary/CEO of subsidiary | 3 | — | — | 2 | −16.7% (1) | May 12, 2021 |
| Bernick Brian | Chief Medical Officer | 2 | — | — | 2 | −11.1% (1) | October 29, 2019 |
| Rubric Capital Management LP | 10% owner | 3 | −78.3% (3) | 0% | 1 | −87.3% (1) | January 3, 2023 |
| Russell Angus C. | Director | 4 | +7.6% (2) | 50% | 0 | — | August 26, 2019 |
| Musing Jules A. | Director | 2 | — | — | 1 | −82.0% (1) | March 1, 2019 |
| Rosen David Efraim | 10% owner | 3 | −68.5% (3) | 0% | 0 | — | December 9, 2022 |
| Bisaro Paul | Director | 2 | — | — | 0 | — | August 18, 2021 |
| Segal Nicholas | Director | 1 | — | — | 1 | −16.7% (1) | March 28, 2014 |
| Walker Marlan D | Chief Executive Officer | 0 | — | — | 2 | — | December 7, 2023 |
| Borkowski Edward | EVP, Operations | 0 | — | — | 1 | — | May 12, 2021 |
| Carroll J Martin | Director | 1 | +18.3% (1) | 100% | 0 | — | May 12, 2015 |
| Darecca James | Chief Financial Officer | 0 | — | — | 1 | — | August 12, 2021 |
| Donegan Michael C | CAO and VP of Finance | 0 | — | — | 1 | — | December 2, 2021 |
| Krassan Mitchell | EVP, Chief Strategy Officer | 0 | — | — | 1 | +37.2% (1) | May 22, 2015 |
| Lapenta Robert V Jr | Director | 1 | — | — | 0 | — | May 13, 2014 |
| Ling Karen | Director | 1 | — | — | 0 | — | August 19, 2021 |
| Naughton Gail K | Director | 0 | — | — | 1 | −85.6% (1) | December 8, 2022 |
| Tjon Robin Natalie and related entities | Other | 0 | — | — | 1 | — | December 22, 2010 |
When several insiders traded Therapeuticsmd, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Therapeuticsmd, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −17.5% against the index. After 1 selling crowd, −29.6%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| December 30, 2022 | 2 buying | −41.5% | −42.7% | −83.3% |
| May 29, 2015 | 3 buying | −10.5% | +7.8% | +22.6% |
| March 31, 2014 | 4 selling | −35.1% | −29.6% | −16.7% |